FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560926689> ?p ?o ?g. }

• W2560926689 abstract "Abstract Abstract 453 Background: Imatinib (IM) 400 mg daily is the standard treatment for Ph+ Chronic Myeloid Leukemia (CML) in early Chronic Phase (ECP). Nilotinib (NIL) is a 2nd generation tyrosine kinase inhibitor (TKI) with superior efficacy to IM (phase 3 ENESTnd trial). NIL has been approved for the frontline treatment of CML in many countries. The treatment with more than one TKI, according to the principles of cancer polychemotherapy, may improve the response rates and may decrease the frequency of drug-resistance. The combination of different TKIs is potentially toxic, difficult to be explored in the ECP setting. The sequential administration of IM and NIL is worth to be investigated because a significant proportion of CML patients treated with a single TKI as monotherapy develops primary or secondary resistance. Aims: To evaluate the response (either cytogenetic and molecular) and the outcome of ECP Ph+ CML patients treated with the sequential administration of NIL and IM. Methods: A phase 2 study was conducted by the GIMEMA CML WP (ClinicalTrials.gov. NCT00769327). NIL was administered first because it has a more rapid therapeutic effect. Schedule: NIL 400 mg twice daily for 3 months; IM 400 mg daily for the next 3 months; then, NIL and IM turning every 3 months, for a total duration of 24 months (study core). The 3-month rotation schedule was respected, irrespectively of temporary discontinuations. The primary end-point was the Complete Cytogenetic Response (CCgR) rate at 12 months. If the conventional cytogenetic analysis resulted not evaluable, a FISH analysis was performed. If one of the 2 drugs was permanently discontinued for adverse event (AE), the patient remained in study, continuing the treatment with the other drug (except for cardiac AEs). Definitions: Major Molecular Response (MMR): BCR-ABL/ABL ratio < 0,1%IS; failure: according to 2009 ELN recommendations; event: failure, permanent discontinuation of both drug for any reason, patient refusal. All the analysis were performed according to the ITT principle. Results: 123 patients have been enrolled in 38 italian hematologic Centers; median age 56 years (range 18–84); 33% low, 45% intermediate and 22% high Sokal score; median follow-up 21 months (at least 12 months observation, 24 months by November 2011). The cumulative CCgR rate by 12 months was 87%; CCgR at each milestone: 68% at 3 months, 73% at 6 months, 67% at 12 months (primary efficacy variable). The cumulative MMR rate by 12 months was 82%, while the rates of MMR at 3, 6 and 12 months were 59%, 62% and 60%, respectively. The discrepancies between cumulative response rates and response at each timepoint were mainly due to the number of patients not evaluable at each timepoint (10% of cytogenetic analysis not evaluable at 12 months) and to protocol discontinuation in stable CCgR and/or MMR. The incidence of hematologic AEs was low. Non-hematologic AEs or lab abnormalities grade > 2 observed in >5 % of patients were as follows: NIL - skin rash, pruritus, bilirubin increase, transaminase increase, lipase increase; IM - fluid retention, periorbital edema. AEs were manageable with appropriate dose adaptations. Four patients (3%) showed a prolongation of the QTcF above 450 msec (none above 500 msec). At the end of the first 12 months, 95 patients (77%) remained on study: 6 and 3 on NIL and IM monotherapy, respectively, 86 on sequential treatment with both drugs; 15% of patients permanently reduced the NIL dose to 400 mg daily and 9% of patients permanently reduced the IM dose to 300 mg daily. During the first year, 28 patients (23%) experienced an event: 10 treatment failure (8%); 2 death in CP (2%); 16 refusal, protocol violation or AE (13%). Six out of the 10 patients who failed the treatment progressed to advanced phase (3 patients: detection of a T315I mutation). Conclusions: The cumulative response rates achieved with a sequential administration of NIL and IM seem to be superior to the historical data of IM alone. The response rates at each timepoint, lower than expected, were probably due to the high number of not evaluable patients and to the number of patients not continuing the study despite a stable CCgR/MMR. However, if compared to the excellent results of 2nd generation TKI as monotherapy in ECP CML (single and randomized trials), the present analysis do not support an alternating schedule of NIL and IM as frontline treatment of ECP CML. Acknowledgments: European LeukemiaNet, COFIN, Bologna University, BolognAIL Disclosures: Castagnetti: Novartis Pharma: Honoraria; Bristol-Myers Squibb: Honoraria. Rosti:Novartis: Consultancy; Bristol Myers Squibb: Consultancy; Novartis: Research Funding; Novartis: Honoraria; Bristol Myers Squibb: Honoraria. Soverini:Novartis: Consultancy; ARIAD: Consultancy; Bristol-Myers Squibb: Consultancy. Martinelli:Bristol-Myers Squibb: Consultancy; Novartis: Consultancy, Research Funding." @default.
• W2560926689 created "2017-01-06" @default.
• W2560926689 creator A5000529499 @default.
• W2560926689 creator A5002133396 @default.
• W2560926689 creator A5002237220 @default.
• W2560926689 creator A5004633066 @default.
• W2560926689 creator A5006110055 @default.
• W2560926689 creator A5008958861 @default.
• W2560926689 creator A5009003698 @default.
• W2560926689 creator A5016041461 @default.
• W2560926689 creator A5020333760 @default.
• W2560926689 creator A5026176228 @default.
• W2560926689 creator A5026992937 @default.
• W2560926689 creator A5027532653 @default.
• W2560926689 creator A5031714115 @default.
• W2560926689 creator A5035566807 @default.
• W2560926689 creator A5042253704 @default.
• W2560926689 creator A5044224344 @default.
• W2560926689 creator A5049790333 @default.
• W2560926689 creator A5057084037 @default.
• W2560926689 creator A5057593886 @default.
• W2560926689 creator A5061902084 @default.
• W2560926689 creator A5063427645 @default.
• W2560926689 creator A5073761054 @default.
• W2560926689 creator A5078324992 @default.
• W2560926689 creator A5080563685 @default.
• W2560926689 creator A5089760320 @default.
• W2560926689 date "2011-11-18" @default.
• W2560926689 modified "2023-09-29" @default.
• W2560926689 title "Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party" @default.
• W2560926689 doi "https://doi.org/10.1182/blood.v118.21.453.453" @default.
• W2560926689 hasPublicationYear "2011" @default.
• W2560926689 type Work @default.
• W2560926689 sameAs 2560926689 @default.
• W2560926689 citedByCount "1" @default.
• W2560926689 countsByYear W25609266892013 @default.
• W2560926689 crossrefType "journal-article" @default.
• W2560926689 hasAuthorship W2560926689A5000529499 @default.
• W2560926689 hasAuthorship W2560926689A5002133396 @default.
• W2560926689 hasAuthorship W2560926689A5002237220 @default.
• W2560926689 hasAuthorship W2560926689A5004633066 @default.
• W2560926689 hasAuthorship W2560926689A5006110055 @default.
• W2560926689 hasAuthorship W2560926689A5008958861 @default.
• W2560926689 hasAuthorship W2560926689A5009003698 @default.
• W2560926689 hasAuthorship W2560926689A5016041461 @default.
• W2560926689 hasAuthorship W2560926689A5020333760 @default.
• W2560926689 hasAuthorship W2560926689A5026176228 @default.
• W2560926689 hasAuthorship W2560926689A5026992937 @default.
• W2560926689 hasAuthorship W2560926689A5027532653 @default.
• W2560926689 hasAuthorship W2560926689A5031714115 @default.
• W2560926689 hasAuthorship W2560926689A5035566807 @default.
• W2560926689 hasAuthorship W2560926689A5042253704 @default.
• W2560926689 hasAuthorship W2560926689A5044224344 @default.
• W2560926689 hasAuthorship W2560926689A5049790333 @default.
• W2560926689 hasAuthorship W2560926689A5057084037 @default.
• W2560926689 hasAuthorship W2560926689A5057593886 @default.
• W2560926689 hasAuthorship W2560926689A5061902084 @default.
• W2560926689 hasAuthorship W2560926689A5063427645 @default.
• W2560926689 hasAuthorship W2560926689A5073761054 @default.
• W2560926689 hasAuthorship W2560926689A5078324992 @default.
• W2560926689 hasAuthorship W2560926689A5080563685 @default.
• W2560926689 hasAuthorship W2560926689A5089760320 @default.
• W2560926689 hasConcept C126322002 @default.
• W2560926689 hasConcept C197934379 @default.
• W2560926689 hasConcept C203092338 @default.
• W2560926689 hasConcept C2777413986 @default.
• W2560926689 hasConcept C2777583451 @default.
• W2560926689 hasConcept C2778375690 @default.
• W2560926689 hasConcept C2778729363 @default.
• W2560926689 hasConcept C3019892230 @default.
• W2560926689 hasConcept C31760486 @default.
• W2560926689 hasConcept C535046627 @default.
• W2560926689 hasConcept C71924100 @default.
• W2560926689 hasConcept C90924648 @default.
• W2560926689 hasConceptScore W2560926689C126322002 @default.
• W2560926689 hasConceptScore W2560926689C197934379 @default.
• W2560926689 hasConceptScore W2560926689C203092338 @default.
• W2560926689 hasConceptScore W2560926689C2777413986 @default.
• W2560926689 hasConceptScore W2560926689C2777583451 @default.
• W2560926689 hasConceptScore W2560926689C2778375690 @default.
• W2560926689 hasConceptScore W2560926689C2778729363 @default.
• W2560926689 hasConceptScore W2560926689C3019892230 @default.
• W2560926689 hasConceptScore W2560926689C31760486 @default.
• W2560926689 hasConceptScore W2560926689C535046627 @default.
• W2560926689 hasConceptScore W2560926689C71924100 @default.
• W2560926689 hasConceptScore W2560926689C90924648 @default.
• W2560926689 hasLocation W25609266891 @default.
• W2560926689 hasOpenAccess W2560926689 @default.
• W2560926689 hasPrimaryLocation W25609266891 @default.
• W2560926689 hasRelatedWork W1019829508 @default.
• W2560926689 hasRelatedWork W2296455122 @default.
• W2560926689 hasRelatedWork W2300265842 @default.
• W2560926689 hasRelatedWork W2344860349 @default.
• W2560926689 hasRelatedWork W2546777028 @default.
• W2560926689 hasRelatedWork W2549736790 @default.
• W2560926689 hasRelatedWork W2552717129 @default.
• W2560926689 hasRelatedWork W2555878248 @default.
• W2560926689 hasRelatedWork W2564004309 @default.
• W2560926689 hasRelatedWork W2565556836 @default.
• W2560926689 hasRelatedWork W2572758957 @default.

• next